NCT07188103 2025-09-23
Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
Anhui Provincial Hospital
Phase 2 Recruiting
Clinical Trials
7 trialsNCT05355168 2024-12-31
Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma
Anhui Provincial Hospital
Phase 2 Completed
NCT06468644 2024-06-21
Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06468670 2024-06-21
Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT05007145 2021-12-21
REVO
Fujian Cancer Hospital
Phase 2 Unknown
NCT04063683 2021-08-24
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.
Henan Cancer Hospital
Phase 2 Unknown
NCT04229849 2020-01-18
Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital
Phase 2 Unknown